Zosano Pharma Corp (NASDAQ:ZSAN) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price target of $4.00 for the company and are anticipating that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given Zosano Pharma an industry rank of 110 out of 265 based on the ratings given to its competitors.
Separately, ValuEngine raised Zosano Pharma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
An institutional investor recently raised its position in Zosano Pharma stock. Vanguard Group Inc. lifted its stake in Zosano Pharma Corp (NASDAQ:ZSAN) by 20.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,217,323 shares of the biotechnology company’s stock after buying an additional 209,251 shares during the quarter. Vanguard Group Inc. owned approximately 3.11% of Zosano Pharma worth $1,716,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.41% of the company’s stock.
Shares of Zosano Pharma (ZSAN) traded down $0.03 during trading hours on Friday, reaching $0.70. The company had a trading volume of 389,800 shares, compared to its average volume of 1,478,545. Zosano Pharma has a 12 month low of $0.56 and a 12 month high of $3.54.
Zosano Pharma (NASDAQ:ZSAN) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.05). equities analysts predict that Zosano Pharma will post -0.9 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Zosano Pharma Corp (ZSAN) Given $4.00 Consensus Target Price by Brokerages” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2018/01/12/zosano-pharma-corp-zsan-given-4-00-consensus-target-price-by-brokerages.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.